AllianceBernstein’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.77B Sell
3,910,786
-585,696
-13% -$273M 0.57% 25
2025
Q4
$2.04B Sell
4,496,482
-26,104
-0.6% -$11.3M 0.64% 22
2025
Q3
$1.77B Buy
4,522,586
+144,266
+3% +$60.3M 0.56% 28
2025
Q2
$1.95B Buy
4,378,320
+424,808
+11% +$196M 0.64% 25
2025
Q1
$1.92B Buy
3,953,512
+33,492
+0.9% +$15.6M 0.69% 21
2024
Q4
$1.58B Sell
3,920,020
-3,452,747
-47% -$1.6B 0.54% 33
2024
Q3
$3.43B Buy
7,372,767
+151,695
+2% +$72.9M 1.15% 14
2024
Q2
$3.38B Buy
7,221,072
+123,791
+2% +$53.7M 1.18% 11
2024
Q1
$2.97B Buy
7,097,281
+57,543
+0.8% +$24.3M 1.05% 11
2023
Q4
$2.86B Sell
7,039,738
-486,718
-6% -$180M 1.1% 11
2023
Q3
$2.62B Sell
7,526,456
-8,578
-0.1% -$3M 1.11% 9
2023
Q2
$2.65B Sell
7,535,034
-838,239
-10% -$282M 1.08% 9
2023
Q1
$2.64B Sell
8,373,273
-696,307
-8% -$209M 1.13% 9
2022
Q4
$2.62B Sell
9,069,580
-75,936
-0.8% -$23.1M 1.18% 9
2022
Q3
$2.65B Sell
9,145,516
-154,714
-2% -$44.5M 1.28% 9
2022
Q2
$2.62B Sell
9,300,230
-1,254,811
-12% -$336M 1.2% 10
2022
Q1
$2.75B Buy
10,555,041
+111,270
+1% +$26.4M 1.06% 14
2021
Q4
$2.29B Buy
10,443,771
+1,374,923
+15% +$267M 0.81% 16
2021
Q3
$1.64B Buy
9,068,848
+2,690,416
+42% +$525M 0.65% 21
2021
Q2
$1.29B Sell
6,378,432
-1,480,175
-19% -$310M 0.52% 28
2021
Q1
$1.69B Sell
7,858,607
-83,154
-1% -$18.3M 0.74% 16
2020
Q4
$1.88B Buy
7,941,761
+1,342,210
+20% +$308M 0.89% 14
2020
Q3
$1.8B Buy
6,599,551
+813,580
+14% +$224M 0.97% 12
2020
Q2
$1.68B Sell
5,785,971
-407,880
-7% -$111M 0.99% 12
2020
Q1
$1.47B Sell
6,193,851
-167,782
-3% -$38.5M 1.06% 11
2019
Q4
$1.39B Buy
6,361,633
+580,418
+10% +$117M 0.79% 16
2019
Q3
$979M Buy
5,781,215
+686,812
+13% +$122M 0.61% 27
2019
Q2
$934M Buy
5,094,403
+1,777,171
+54% +$311M 0.58% 33
2019
Q1
$610M Buy
3,317,232
+386,502
+13% +$71.4M 0.4% 56
2018
Q4
$486M Buy
2,930,730
+2,394,289
+446% +$415M 0.36% 61
2018
Q3
$103M Buy
536,441
+40,336
+8% +$7.18M 0.07% 298
2018
Q2
$84.3M Buy
496,105
+29,847
+6% +$4.63M 0.06% 352
2018
Q1
$76M Sell
466,258
-5,020
-1% -$820K 0.05% 366
2017
Q4
$70.6M Sell
471,278
-7,016
-1% -$1.04M 0.05% 404
2017
Q3
$72.7M Buy
478,294
+34,642
+8% +$5.21M 0.05% 382
2017
Q2
$57.2M Buy
443,652
+4,164
+0.9% +$501K 0.04% 445
2017
Q1
$48.1M Sell
439,488
-14,469
-3% -$1.27M 0.04% 484
2016
Q4
$33.4M Sell
453,957
-12,092
-3% -$984K 0.03% 564
2016
Q3
$40.6M Buy
466,049
+1,358
+0.3% +$128K 0.03% 505
2016
Q2
$40M Buy
464,691
+7,491
+2% +$647K 0.03% 480
2016
Q1
$36.3M Sell
457,200
-3,775
-0.8% -$341K 0.03% 511
2015
Q4
$58M Sell
460,975
-1,999
-0.4% -$241K 0.05% 407
2015
Q3
$48.2M Sell
462,974
-5,942
-1% -$763K 0.04% 445
2015
Q2
$57.9M Sell
468,916
-92,272
-16% -$11.6M 0.05% 434
2015
Q1
$66.2M Sell
561,188
-71,004
-11% -$8.51M 0.05% 391
2014
Q4
$75.1M Sell
632,192
-68,841
-10% -$7.75M 0.06% 336
2014
Q3
$78.7M Sell
701,033
-677,587
-49% -$64.5M 0.07% 328
2014
Q2
$131M Sell
1,378,620
-1,266,303
-48% -$88.8M 0.11% 208
2014
Q1
$187M Buy
2,644,923
+227,282
+9% +$18M 0.16% 146
2013
Q4
$180M Buy
2,417,641
+428,030
+22% +$29.8M 0.16% 149
2013
Q3
$151M Sell
1,989,611
-491,244
-20% -$39.1M 0.15% 151
2013
Q2
$198M Buy
+2,480,855
New +$183M 0.21% 111

Other funds holding VRTX

AllianceBernstein's VRTX Position: Q1 2026 in Review

AllianceBernstein reduced its Vertex Pharmaceuticals (VRTX) stake by 13% in Q1 2026, selling an estimated $273M and leaving 3,910,786 shares worth $1.77B. The position accounts for 0.57% of the portfolio, ranked #25.

AllianceBernstein first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $3.43B in Q3 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • AllianceBernstein held 3,910,786 shares of Vertex Pharmaceuticals worth $1.77B as of Q1 2026.
  • AllianceBernstein sold 585,696 Vertex Pharmaceuticals shares in Q1 2026, an estimated $273M.
  • Vertex Pharmaceuticals made up 0.57% of AllianceBernstein's portfolio in Q1 2026, its #25 holding.
  • AllianceBernstein first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • AllianceBernstein's Vertex Pharmaceuticals position peaked at $3.43B in Q3 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.